Insight Article Desktop Banner
Global Equity Observer
July 23, 2021

Quality in a Brave New World

Insight Video Mobile Banner
July 23, 2021

Quality in a Brave New World

Global Equity Observer

Quality in a Brave New World

Share Icon

July 23, 2021


The last quarter century since the inception of our team’s longest-standing global strategy has proved fertile ground for high quality compounders. Their combination of pricing power and recurring revenues has allowed them to comfortably out-earn the market as a whole, helped by the disasters that befell the technology, media and telecommunications (TMT) sector in the 2001-03 crash and the financials sector in the 2008-09 Global Financial Crisis. The other positive has been that, despite this superior record, they have generally only traded at a mild premium to the market, particularly when looking at free cash flow yields.


There is speculation that quality and compounders will struggle in the “Brave New World” of reflation and inflation. Our view is that the companies should continue to prosper, even if there is a shift to a more inflationary regime.

It is true that the last year has been less favourable for quality in relative terms. The first issue was that 2020 saw a growth boom, as investors got excited about a lot of the technological winners from the pandemic. Our view is that elements of this turned into a bubble, with some extreme valuations and speculative excesses around special purpose acquisition companies (SPACs). Our valuation discipline meant that we did not participate in this exuberance. On top of that, the fourth quarter of 2020 and first quarter of 2021 saw significant good news around the speed of vaccine development and rollout, which sharply accelerated the likely path of recovery. As a result, the value sectors and cyclical recovery plays in sectors such as financials, materials and industrials naturally came into favour, as their earnings expectations improved sharply in the “reflation trade”, comfortably outpacing the defensive sectors – notably consumer staples and health care – that make up much of our global portfolios.

Last year’s growth bubble has deflated somewhat in 2021, with information technology’s most expensive quintile only returning 3% year-to-date, against an average of 12% for the other four quintiles.1 The median valuation in the top quintile has dropped from around 130x 24-month forward earnings to a mere 110x or so.1 (This is provided you are kind enough to exclude stock-based compensation from their costs – otherwise the median stock in the quintile is loss-making.) As a result, in the near term much of the discussion is around how much legs the cyclical, or reflation, trade still has left.

It is unclear whether there are further positive growth surprises to come, how much upside still remains in cyclical earnings, and the extent to which any good news is already in stock prices, with materials up 82% and financials up 74% since March 2020, compared with only 32% for consumer staples and 42% for health care.1 The experience of the second quarter of 2021, with the cyclical sectors generally lagging slightly behind the overall index, suggests that the momentum behind the value trade may be fading.

Inflation watch

The fear is that the current economic boom will drive inflation, and prices have indeed already risen sharply for many commodities and products. What is not yet clear is how much of this is transitory – the result of spikes in demand and supply still constrained by the pandemic – and how much may prove to be permanent. The consensus seems to be that much of the inflationary pressure will indeed fade away as demand normalises and supply recovers, meaning that governments will not have to slam on the brakes.

We would agree that some commodities, for instance iron ore, are above likely long-term prices (which incidentally means that their producers may be over-earning at present). The key inflation variable to watch is wage growth: in service-orientated economies, people costs are more important than the costs of “stuff”, be it semiconductors or lumber. In the meantime, the market obsesses over tiny micro-signals about central bank intentions, reminiscent of the Cold War sport of Kremlinology, described by one eminent historian of the time as the attempt to work out who was winning the power struggles within the Politburo by the width of the black armbands worn at public state funerals in Red Square.

Looking through the timing and strength of the current economic recovery, there are longer-term concerns in the market about the fate of quality equities in a higher-inflation world, if that does indeed come to pass. While we do not have a strong view as to the likely path of inflation, given that there are decent arguments for both the transitory and the more permanent cases, we do believe that quality companies can still thrive in a more inflationary environment.

One key point to make is that inflation is fundamentally a nominal rather than a real phenomenon. It will accelerate headline revenue growth rates, but any benefits are illusionary as they are cancelled out by the rise in the price level. That said, there are arguments that inflation can particularly help lower quality companies. “Money illusion” can fool people into crediting companies that are not growing in real terms with growth status – not something that happens in today’s low-inflation world. In addition, inflation may help asset-heavy companies’ accounting profits, as sales rise relative to the book value of their assets and the associated depreciation. The final argument in favour of lower quality stocks in an inflationary regime is that they are less vulnerable to an inflation-driven rise in discount rates as nominal rates rise, given their lower multiple and shorter duration compared with more expensive stocks. This makes sense mathematically … providing you ignore the fact that the long-run nominal growth rate is likely to rise in parallel with the inflation and discount rates, cancelling out any effect on the multiple.

Compounders remain attractive

Overall, our view is that these inflation gains for lower quality companies are not “real” or “economic” and are thus unlikely to have a long-lasting impact, with the exception of some financials, which may see net interest gains from higher interest rates. We would also argue that there are two significant relative pluses for higher quality companies in a higher inflation world:

  • The first is that inflation will mean that companies have to deal with rising input costs. This is likely to put a premium on those companies who can pass those costs on to customers through their pricing power, one of the key characteristics that we look for in compounders.
  • The other is that this regime will probably require more frequent government intervention to keep inflation under control, prompting shorter economic cycles. The last few decades have seen unprecedentedly long economic cycles as governments have not had to slow economies down to dampen price rises, and this is unlikely to be sustained if inflation became an issue. In a world of frequent recessions, compounders’ recurring revenues would be an even more valuable source of earnings stability.

Ultimately, the case for compounders remains largely unchanged in a more inflationary world. Companies that can grow their earnings steadily in real terms across cycles are likely to continue out-earning the market, just as they have done over the last few decades. Pricing power and recurring revenues are arguably even more important in a world of rising input costs and higher economic volatility. In a world of expensive markets, with the MSCI World Index still at a 20x forward multiple for the first time since the TMT bubble at the start of the century - even after a 40% rise in earnings over the last year - compounders remain attractive.1 After all, given that markets currently involve significant valuation risk, why take earnings risk as well?


1 Source: FactSet. Data as of June 2021.


Risk Considerations

There is no assurance that a portfolio will achieve its investment objective. Portfolios are subject to market risk, which is the possibility that the market value of securities owned by the portfolio will decline. Market values can change daily due to economic and other events (e.g. natural disasters, health crises, terrorism, conflicts and social unrest) that affect markets, countries, companies or governments. It is difficult to predict the timing, duration, and potential adverse effects (e.g. portfolio liquidity) of events. Accordingly, you can lose money investing in this strategy. Please be aware that this strategy may be subject to certain additional risks. Changes in the worldwide economy, consumer spending, competition, demographics and consumer preferences, government regulation and economic conditions may adversely affect global franchise companies and may negatively impact the strategy to a greater extent than if the strategy’s assets were invested in a wider variety of companies. In general, equity securities’ values also fluctuate in response to activities specific to a company. Investments in foreign markets entail special risks such as currency, political, economic, and market risks. Stocks of small- and mid-capitalisation companies carry special risks, such as limited product lines, markets and financial resources, and greater market volatility than securities of larger, more established companies. The risks of investing in emerging market countries are greater than risks associated with investments in foreign developed markets. Derivative instruments may disproportionately increase losses and have a significant impact on performance. They also may be subject to counterparty, liquidity, valuation, correlation and market risks. Illiquid securities may be more difficult to sell and value than publicly traded securities (liquidity risk). Non-diversified portfolios often invest in a more limited number of issuers. As such, changes in the financial condition or market value of a single issuer may cause greater volatility. ESG strategies that incorporate impact investing and/or Environmental, Social and Governance (ESG) factors could result in relative investment performance deviating from other strategies or broad market benchmarks, depending on whether such sectors or investments are in or out of favor in the market. As a result, there is no assurance ESG strategies could result in more favorable investment performance.

Managing Director
International Equity Team
Featured Funds


Free cash flow (FCF) is a measure of financial performance calculated as operating cash flow minus capital expenditures. FCF represents the cash that a company is able generate after laying out the money required to maintain or expand its asset base. Return On Operating Capital Employed (ROOCE) is a ratio indicating the efficiency and profitability of a company’s trade working capital. Calculated as: earnings before interest and taxes/property, plant and equipment plus trade working capital (ex-financials and excluding goodwill).


This communication is only intended for and will only be distributed to persons resident in jurisdictions where such distribution or availability would not be contrary to local laws or regulations.

Ireland: MSIM Fund Management (Ireland) Limited. Registered Office: The Observatory, 7-11 Sir John Rogerson's Quay, Dublin 2, D02 VC42, Ireland. Registered in Ireland as a private company limited by shares under company number 616661. MSIM Fund Management (Ireland) Limited is regulated by the Central Bank of Ireland. United Kingdom: Morgan Stanley Investment Management Limited is authorised and regulated by the Financial Conduct Authority. Registered in England. Registered No. 1981121. Registered Office: 25 Cabot Square, Canary Wharf, London E14 4QA, authorised and regulated by the Financial Conduct Authority. Dubai: Morgan Stanley Investment Management Limited (Representative Office, Unit Precinct 3-7th Floor-Unit 701 and 702, Level 7, Gate Precinct Building 3, Dubai  International Financial Centre, Dubai, 506501, United Arab Emirates. Telephone: +97 (0)14 709 7158). Germany: MSIM Fund Management (Ireland) Limited Niederlassung Deutschland, Grosse Gallusstrasse 18, 60312 Frankfurt am Main, Germany (Gattung: Zweigniederlassung (FDI) gem. § 53b KWG). Italy: MSIM Fund Management (Ireland)Limited, Milan Branch (Sede Secondaria di Milano) is a branch of MSIM Fund Management (Ireland) Limited, a company registered in Ireland, regulated by the Central Bank of Ireland and whose registered office is at The Observatory, 7-11 Sir John Rogerson's Quay, Dublin 2, D02 VC42, Ireland. MSIM Fund Management (Ireland) Limited Milan Branch (Sede Secondaria di Milano) with seat in Palazzo Serbelloni Corso Venezia, 16 20121 Milano, Italy, is registered in Italy with company number and VAT number 11488280964. The Netherlands: MSIM Fund Management (Ireland) Limited, Rembrandt Tower, 11th Floor Amstelplein 1 1096HA, Netherlands. Telephone: 31 2-0462-1300. Morgan Stanley Investment Management is a branch office of MSIM Fund Management (Ireland) Limited. MSIM Fund Management (Ireland) Limited is regulated by the Central Bank of Ireland. France: MSIM Fund Management (Ireland) Limited, Paris Branch is a branch of MSIM Fund Management (Ireland) Limited, a company registered in Ireland, regulated by the Central Bank of Ireland and whose registered office is at The Observatory, 7-11 Sir John Rogerson's Quay, Dublin 2, D02 VC42, Ireland. MSIM Fund Management (Ireland) Limited Paris Branch with seat at 61 rue de Monceau 75008 Paris, France, is registered in France with company number 890 071 863 RCS. Spain: MSIM Fund Management (Ireland) Limited, Sucursal en España is a branch of MSIM Fund Management (Ireland) Limited, a company registered in Ireland, regulated by the Central Bank of Ireland and whose registered office is at The Observatory, 7-11 Sir John Rogerson's Quay, Dublin 2, D02 VC42, Ireland. MSIM Fund Management (Ireland) Limited, Sucursal en España with seat in Calle Serrano 55, 28006, Madrid, Spain, is registered in Spain with tax identification number W0058820B.  Switzerland: Morgan Stanley & Co. International plc, London, Zurich Branch Authorised and regulated by the Eidgenössische Finanzmarktaufsicht (“FINMA”). Registered with the Register of Commerce Zurich CHE-115.415.770. Registered Office: Beethovenstrasse 33, 8002 Zurich, Switzerland, Telephone +41 (0) 44 588 1000. Facsimile Fax: +41(0) 44 588 1074.


A separately managed account may not be appropriate for all investors. Separate accounts managed according to the Strategy include a number of securities and will not necessarily track the performance of any index. Please consider the investment objectives, risks and fees of the Strategy carefully before investing. A minimum asset level is required. For important information about the investment manager, please refer to Form ADV Part 2.

Please consider the investment objectives, risks, charges and expenses of the funds carefully before investing. The prospectuses contain this and other information about the funds. To obtain a prospectus please download one at or call 1-800-548-7786. Please read the prospectus carefully before investing.

Morgan Stanley Distribution, Inc. serves as the distributor for Morgan Stanley funds.


Hong Kong: This document has been issued by Morgan Stanley Asia Limited for use in Hong Kong and shall only be made available to “professional investors” as defined under the Securities and Futures Ordinance of Hong Kong (Cap 571). The contents of this document have not been reviewed nor approved by any regulatory authority including the Securities and Futures Commission in Hong Kong. Accordingly, save where an exemption is available under the relevant law, this document shall not be issued, circulated, distributed, directed at, or made available to, the public in Hong Kong. Singapore: This document should not be considered to be the subject of an invitation for subscription or purchase, whether directly or indirectly, to the public or any member of the public in Singapore other than (i) to an institutional investor under section 304 of the Securities and Futures Act, Chapter 289 of Singapore (“SFA”); (ii) to a “relevant person” (which includes an accredited investor) pursuant to section 305 of the SFA, and such distribution is in accordance with the conditions specified in section 305 of the SFA; or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. This publication has not been reviewed by the Monetary Authority of Singapore. Australia: This publication is disseminated in Australia by Morgan Stanley Investment Management (Australia) Pty Limited ACN: 122040037, AFSL No. 314182, which accept responsibility for its contents. This publication, and any access to it, is intended only for “wholesale clients” within the meaning of the Australian Corporations Act.

Japan: For professional investors, this document is circulated or distributed for informational purposes only. For those who are not professional investors, this document is provided in relation to Morgan Stanley Investment Management (Japan) Co., Ltd. (“MSIMJ”)’s business with respect to discretionary investment management agreements (“IMA”) and investment advisory agreements (“IAA”). This is not for the purpose of a recommendation or solicitation of transactions or offers any particular financial instruments. Under an IMA, with respect to management of assets of a client, the client prescribes basic management policies in advance and commissions MSIMJ to make all investment decisions based on an analysis of the value, etc. of the securities, and MSIMJ accepts such commission. The client shall delegate to MSIMJ the authorities necessary for making investment. MSIMJ exercises the delegated authorities based on investment decisions of MSIMJ, and the client shall not make individual instructions. All investment profits and losses belong to the clients; principal is not guaranteed. Please consider the investment objectives and nature of risks before investing. As an investment advisory fee for an IAA or an IMA, the amount of assets subject to the contract multiplied by a certain rate (the upper limit is 2.20% per annum (including tax)) shall be incurred in proportion to the contract period. For some strategies, a contingency fee may be incurred in addition to the fee mentioned above. Indirect charges also may be incurred, such as brokerage commissions for incorporated securities. Since these charges and expenses are different depending on a contract and other factors, MSIMJ cannot present the rates, upper limits, etc. in advance. All clients should read the Documents Provided Prior to the Conclusion of a Contract carefully before executing an agreement. This document is disseminated in Japan by MSIMJ, Registered No. 410 (Director of Kanto Local Finance Bureau (Financial Instruments Firms)), Membership: the Japan Securities Dealers Association, The Investment Trusts Association, Japan, the Japan Investment Advisers Association and the Type II Financial Instruments Firms Association.


EMEA: This marketing communication has been issued by MSIM Fund Management (Ireland) Limited. MSIM Fund Management (Ireland) Limited is regulated by the Central Bank of Ireland. MSIM Fund Management (Ireland) Limited is incorporated in Ireland as a private company limited by shares with company registration number 616661 and has its registered address at The Observatory, 7-11 Sir John Rogerson's Quay, Dublin 2, D02 VC42,  Ireland.

There is no guarantee that any investment strategy will work under all market conditions, and each investor should evaluate their ability to invest for the long-term, especially during periods of downturn in the market. Prior to investing, investors should carefully review the strategy’s/product’s relevant offering document. There are important differences in how the strategy is carried out in each of the investment vehicles.

A separately managed account may not be appropriate for all investors. Separate accounts managed according to the Strategy include a number of securities and will not necessarily track the performance of any index. Please consider the investment objectives, risks and fees of the Strategy carefully before investing.

This material is a general communication, which is not impartial and has been prepared solely for informational and educational purposes and does not constitute an offer or a recommendation to buy or sell any particular security or to adopt any specific investment strategy. The information herein has not been based on a consideration of any individual investor circumstances and is not investment advice, nor should it be construed in any way as tax, accounting, legal or regulatory advice. To that end, investors should seek independent legal and financial advice, including advice as to tax consequences, before making any investment decision.

Except as otherwise indicated herein, the views and opinions expressed herein are those of the portfolio management team, are based on matters as they exist as of the date of preparation and not as of any future date, and will not be updated or otherwise revised to reflect information that subsequently becomes available or circumstances existing, or changes occurring, after the date hereof.

Forecasts and/or estimates provided herein are subject to change and may not actually come to pass. Information regarding expected market returns and market outlooks is based on the research, analysis and opinions of the authors. These conclusions are speculative in nature, may not come to pass and are not intended to predict the future performance of any specific Morgan Stanley Investment Management product.

MSIM has not authorised financial intermediaries to use and to distribute this document, unless such use and distribution is made in accordance with applicable law and regulation.

Additionally, financial intermediaries are required to satisfy themselves that the information in this document is appropriate for any person to whom they provide this document in view of that person’s circumstances and purpose. MSIM shall not be liable for, and accepts no liability for, the use or misuse of this document by any such financial intermediary.

The whole or any part of this work may not be directly or indirectly reproduced, copied, modified, used to create a derivative work, performed, displayed,  published, posted, licensed, framed, distributed or transmitted or any of its contents disclosed to third parties without MSIM’s express written consent. This work may not be linked to unless such hyperlink is for personal and non-commercial use. All information contained herein is proprietary and is protected under copyright and other applicable law.

All information contained herein is proprietary and is protected under copyright law.


This is a Marketing Communication.

It is important that users read the Terms of Use before proceeding as it explains certain legal and regulatory restrictions applicable to the dissemination of information pertaining to Morgan Stanley Investment Management's investment products.

The services described on this website may not be available in all jurisdictions or to all persons. For further details, please see our Terms of Use.

Privacy & Cookies    •    Terms of Use

©  Morgan Stanley. All rights reserved.